Patritumab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase III program in Non-Small Cell Lung Cancer. According to Globaldata, it is involved in 11 clinical trials, of which 1 was completed, 8 are ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Patritumab deruxtecan’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Patritumab deruxtecan is expected to reach an annual total of $30 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Patritumab deruxtecan Overview
Patritumab deruxtecan (U-31402) is under development for the treatment of HER3-positive metastatic or unresectable breast cancer, human epidermal growth factor receptor 2 negative breast cancer, squamous or non-squamous non-small cell lung cancer, melanoma, intestinal cancer, ovarian cancer, cholangiocarcinoma, prostate cancer and triple negative breast cancer. It is administered intravenously. The drug candidate is a humanized anti-HER3 antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). It is developed based on proprietary payload and linker-payload technology. It was also under development for bladder cancer and skin cancer.
It was under development for the treatment of metastatic colorectal cancer, colon cancer and rectal adenocarcinoma.
Daiichi Sankyo Overview
Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
The company reported revenues of (Yen) JPY1,044,892 million for the fiscal year ended March 2022 (FY2022), an increase of 8.6% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 7% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 7.9% in FY2021. The company reported revenues of JPY340,479 million for the third quarter ended December 2022, an increase of 4% over the previous quarter.
For a complete picture of Patritumab deruxtecan’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.